As a rapidly emerging generic pharmaceutical company, Vensun has filed several Abbreviated New Drug Applications (ANDAs) with the FDA through its partnerships and currently has over 30 products in active development. We are actively seeking additional opportunities for partnerships, strategic alliances, and product acquisitions to enhance our existing development portfolio.
Funding Rounds (3) - $25.51MUpdate
Current Team (2)Update
|Mar 1, 2015||SEC - SEC FORM D|
|Oct 14, 2013||PE HUB - Vensun Pharmaceuticals nabs $15.8 mln in Series B financing|
|Aug 27, 2013||SEC - SEC FORM D|
790 Township Line Rd
Yardley, PA 19067